Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology Identifier:
First received: March 7, 2000
Last updated: July 1, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2010
  Primary Completion Date: March 2003 (Final data collection date for primary outcome measure)
Rai KR, Byrd JC, Peterson B: Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. [Abstract] Blood 102 (11 Pt 1): A-2506, 2003.
Rai KR, Byrd JC, Peterson BL, et al.: A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901. [Abstract] Blood 100 (11 Pt 1): A-772, 2002.

Publications automatically indexed to this study by Identifier (NCT Number):